Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension

Clinical Therapeutics

Volumn 18, Issue 4, 1996, Pages 608-625

  Oparil, Suzanne ^a   Barr, Eliav ^b   Elkins, Michelle ^b   Liss, Charles ^c   Vrecenak, Arthur ^b   Edelman, Jonathan ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b US Human Health   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOSARTAN; LOSARTAN POTASSIUM; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; SITTING; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0029785679     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80212-8     Document Type: Article

References (14)

1. Heart and Stroke Facts: 1994 Statistical Supplement. Dallas, Tex: American Heart Association; 1996.
2. Burl VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult U.S. population. Data from the health examination survey, 1960 to 1991. Hypertension. 1995;26:60-69.
3. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
4. Weber MA. Controversies in the diagnosis and treatment of hypertension: A personal review of JNC V. Am J Cardiol. 1993;72:3H-9H.
5. Hypertension Detection and Follow-up Program Cooperative. Five year findings of the hypertension detection and follow-up program. JAMA. 1979;242:2562-2571.
6. Market Measures, Inc. Therapeutic class studies: Treatment of hypertension. November, 1993.
7. Dzau VJ. Evolving concepts of the renin-angiotensin system. Focus on renal and vascular mechanism. Am J Hypertens. 1988;1:334S-337S.
8. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
9. Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate hypertension. Am J Hypertens. 1995;8:578-583.
10. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25: 1345-1350.
11. Cummings DM, Amadio P, Nelson L, Fitzgerald JM. The role of calcium channel blockers in the treatment of essential hypertension. Arch Intern Med. 1991;151: 250-259.
12. Levine S, Croog SH. What constitutes quality of life? A conceptualization of the dimensions of life quality in healthy populations and patients with cardiovascular disease. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of Quality of Life, in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing, Inc; 1984:46-58.
13. Dahlof C. Well being (quality of life) in connection with hypertensive treatment. Clin Cardiol. 1991;14:97-103.
14. Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther. 1996; 18:411-428.